Goodwin Biotechnology Expands Bioconjugation Capacity
By

Goodwin Biotechnology, a biological contract development and manufacturing organization, has expanded its bioconjugation capabilities by adding a dedicated suite for developing and manufacturing cytotoxic antibody drug conjugates up to Safebridge Level 4/5.

The SafeBridge Potent Compound Safety Certification program provides an independent assessment of a company’s manufacturing company’s capabilities for safe production of potent active pharmaceutical ingredients and drug products.

Goodwin Biotechnology is based in Plantation, Florida. It occupies a facility of over 28,000 square feetfor GMP manufacturing and process development, quality assurance and quality control labs and support services.

Source: Goodwin Biotechnology

Leave a Reply

Your email address will not be published. Required fields are marked *